No-Observed-Adverse-Effect Level

"No-Observed-Adverse-Effect Level" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The highest dosage administered that does not produce toxic effects.

Descriptor ID	D019055
MeSH Number(s)	E05.940.600 G07.690.936.750
Concept/Terms	No-Observed-Adverse-Effect Level No-Observed-Adverse-Effect Level Level, No-Observed-Adverse-Effect Levels, No-Observed-Adverse-Effect No Observed Adverse Effect Level No-Observed-Adverse-Effect Levels NOAEL No-Observed-Effect Level No-Observed-Effect Level Level, No-Observed-Effect Levels, No-Observed-Effect No Observed Effect Level No-Observed-Effect Levels Acceptable Daily Intake Acceptable Daily Intake Acceptable Daily Intakes Daily Intake, Acceptable Daily Intakes, Acceptable Intake, Acceptable Daily Intakes, Acceptable Daily Tolerable Daily Intake Daily Intake, Tolerable Daily Intakes, Tolerable Intake, Tolerable Daily Intakes, Tolerable Daily Tolerable Daily Intakes

Below are MeSH descriptors whose meaning is more general than "No-Observed-Adverse-Effect Level".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Toxicity Tests [E05.940]
No-Observed-Adverse-Effect Level [E05.940.600]
Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Toxicological Phenomena [G07.690.936]
No-Observed-Adverse-Effect Level [G07.690.936.750]

Below are MeSH descriptors whose meaning is related to "No-Observed-Adverse-Effect Level".

Below are MeSH descriptors whose meaning is more specific than "No-Observed-Adverse-Effect Level".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "No-Observed-Adverse-Effect Level" by people in this website by year, and whether "No-Observed-Adverse-Effect Level" was a major or minor topic of these publications.

Bar chart showing 7 publications over 5 distinct years, with a maximum of 2 publications in 2004 and 2010

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
2004	2	2
2006	1	1
2010	2	2
2016	1	1
2024	1	1

Below are the most recent publications written about "No-Observed-Adverse-Effect Level" by people in Profiles.

Vom Saal FS, Antoniou M, Belcher SM, Bergman A, Bhandari RK, Birnbaum LS, Cohen A, Collins TJ, Demeneix B, Fine AM, Flaws JA, Gayrard V, Goodson WH, Gore AC, Heindel JJ, Hunt PA, Iguchi T, Kassotis CD, Kortenkamp A, Mesnage R, Muncke J, Myers JP, Nadal A, Newbold RR, Padmanabhan V, Palanza P, Palma Z, Parmigiani S, Patrick L, Prins GS, Rosenfeld CS, Skakkebaek NE, Sonnenschein C, Soto AM, Swan SH, Taylor JA, Toutain PL, von Hippel FA, Welshons WV, Zalko D, Zoeller RT. The Conflict between Regulatory Agencies over the 20,000-Fold Lowering of the Tolerable Daily Intake (TDI) for Bisphenol A (BPA) by the European Food Safety Authority (EFSA). Environ Health Perspect. 2024 Apr; 132(4):45001.

View in: PubMed
Kim JK, Shin JH, Lee JS, Hwang JH, Lee JH, Baek JE, Kim TG, Kim BW, Kim JS, Lee GH, Ahn K, Han SG, Bello D, Yu IJ. 28-Day inhalation toxicity of graphene nanoplatelets in Sprague-Dawley rats. Nanotoxicology. 2016 09; 10(7):891-901.

View in: PubMed
McLain DE, Horn TL, Detrisac CJ, Lindsey CY, Smith LA. Progress in biological threat agent vaccine development: a repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits. Int J Toxicol. 2011 Mar; 30(2):143-52.

View in: PubMed
Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother Pharmacol. 2011 Aug; 68(2):513-24.

View in: PubMed
vom Saal FS, Akingbemi BT, Belcher SM, Crain DA, Crews D, Guidice LC, Hunt PA, Leranth C, Myers JP, Nadal A, Olea N, Padmanabhan V, Rosenfeld CS, Schneyer A, Schoenfelder G, Sonnenschein C, Soto AM, Stahlhut RW, Swan SH, Vandenberg LN, Wang HS, Watson CS, Welshons WV, Zoeller RT. Flawed experimental design reveals the need for guidelines requiring appropriate positive controls in endocrine disruption research. Toxicol Sci. 2010 06; 115(2):612-3.

View in: PubMed
Calabrese EJ, Hoffmann GR, Stanek EJ, Nascarella MA. Hormesis in high-throughput screening of antibacterial compounds in E coli. Hum Exp Toxicol. 2010 Aug; 29(8):667-77.

View in: PubMed
Horn TL, Harder JB, Johnson WD, Curry PT, Parchment RE, Morrissey RL, Mellick PW, Calis KA, Gold PW, Rice KC, Contoreggi C, Charney DS, Cizza G, Glaze ER, Tomaszewski JE, McCormick DL. Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonist. Toxicology. 2008 Jun 03; 248(1):8-17.

View in: PubMed
Calabrese EJ, Staudenmayer JW, Stanek EJ. Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr Opin Drug Discov Devel. 2006 Jan; 9(1):117-23.

View in: PubMed
Zoeller RT, Rice DC. Critical effect of perchlorate on neonates is iodide uptake inhibition. Regul Toxicol Pharmacol. 2004 Dec; 40(3):376-7; author reply 378-9.

View in: PubMed
Boekelheide K, Darney SP, Daston GP, David RM, Luderer U, Olshan AF, Sanderson WT, Willhite CC, Woskie S. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of 2-bromopropane. Reprod Toxicol. 2004 Mar-Apr; 18(2):189-217.

View in: PubMed

People

Explore

Similar Concepts

Top Journals